Storage: Store at room temperature, away from light
Rare diseases
Combining cagrilintide with tirzepatide could theoretically produce 20-30% body weight loss by targeting three distinct pathways (GIP, GLP-1, and amylin), but the lack of clinical data means dosing protocols are speculative, side effect profiles unknown, and safety unclear
BPC-157 lacks FDA approval and remains investigational
If CagriSema receives regulatory approval, it would likely become the standard of care for obesity treatment, potentially displacing semaglutide and tirzepatide as first-line options
Frequently Asked Questions About BPC-157 5mg BPC-157 5mg can be reconstituted in bacteriostatic water, sterile water, or 0.9% sodium chloride solution